Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.

@article{Vance2009GeneticHI,
  title={Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.},
  author={Gail H. Vance and Todd S. Barry and Kenneth J. Bloom and Patrick L. Fitzgibbons and David G. Hicks and R. Brian Jenkins and Diane L. Persons and Raymond R. Tubbs and M Elizabeth Hale Hammond},
  journal={Archives of pathology & laboratory medicine},
  year={2009},
  volume={133 4},
  pages={611-2}
}
CONTEXT Intratumoral heterogeneity of HER2 gene amplification has been well documented and represents subclonal diversity within the tumor. The reported incidence of intratumor HER2 amplification genetic heterogeneity ranges in the literature from approximately 5% to 30%. The presence of HER2 genetic heterogeneity may increase subjectivity in HER2 interpretation by the pathologist. OBJECTIVES To define HER2 genetic heterogeneity and to provide practice guidelines for examining and reporting… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 99 extracted citations

References

Publications referenced by this paper.
Showing 1-8 of 8 references

American Society of Clinical Oncology/College of American Pathologists Guideline recommendation for human epidermal growth factor receptor 2 testing in breast cancer

  • AC Wolf, EH Hammond, JN Schwartz
  • Arch Pathol Lab Med
  • 2007

American Society of Clinical Oncology/College of American Pathologists Guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

  • AC Wolf, EH Hammond, JN Schwartz
  • J Clin Oncol
  • 2007

Similar Papers

Loading similar papers…